You should not miss that!

Are you sometimes lost in the flood of information on LinkedIn about biotechnology?

No worries, here is a summary of what you should not miss last week:

The best gems about biotechnology on LinkedIn

? What are the challenges for biomass? Sara Christina Martinez explains some of them and describes the increasing value. There are so many debates to discuss if we want to use wisely this resource and protect biodiversity.

???? Read her post here.

? If we want to take better care of our planet, we must reduce food loss. Simon Maechling explains the extent of the losses and the reasons. He reports some solutions to these problems. How can we make a difference?

???? Read his post here.

? The growth of biotech can be a challenge for its teams and start an organizational crisis. Philipp Baaske shares his personal experience and illustrates how to fix the situation.

???? Read his post here.

? Do you know the $1 billion Climate and Nature Fund? This fund's goal is to invest where it can influence the whole industry. Eric Soubeiran illustrates how and the priorities according to the region of the world involved.

Read his post here.

? What is the most interesting form of investment for your biotech? Venture Capital or Private Equity?? Brian Ortiz details differences and which of the two corresponds to different stages of a biotech's lifecycle.

Read his post here.

The remarkable fundraising

1?? Hasten Biopharmaceutical Co., Ltd. , has completed a $315 million fundraising round.

The company tries to connect the upstream and downstream industrial chains through the layout of "whole industry" and "globalization", as well as enrich product structure and pipelines in diversified ways. We will work closely with our stakeholders such as relevant government institutions, medical and health professionals and industry partners to continuously drive the management ecosystem of chronic diseases and geriatric-related diseases, aiming to build a leading innovative medical and healthcare enterprise in China to benefit more patients.

???? More information here.

2?? Orbital Therapeutics Secures $270 Million in Series A Financing.

The company a company focused on enhancing global health by unleashing the?full?potential of RNA medicines to treat human disease in ways that were not previously possible. They’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine.

???? More information here.

3?? Vedanta Biosciences, Inc. raises Financing

The company is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the?human microbiome?and grown from pure clonal cell banks.

The company’s clinical-stage pipeline includes product candidates being evaluated for the prevention of recurrent?C. difficile?infection, inflammatory bowel diseases, food allergies, and liver disease.?

???? More information here.

4?? Antiva Biosciences, Inc. ?has cinched a $53 million series E round.

It is a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papillomavirus?(HPV) infection. They are developing a first-in-class therapy that would give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed. Their therapy also provides a non-surgical option for women whose disease is more advanced.

???? More information here.

5?? Evommune closes $50 million Series B Financing.

The company is private clinical-stage biotechnology inventing new ways to treat inflammatory diseases. The company is evolving immunology through its unique and dynamic human tissue-based approach to discovering, developing, and delivering therapies that address symptoms and halt progressive disease.

???? More information here.

Source: Fierce Biotech and Labiotech.eu

Will you be there?

• LSX World conference in London (3-4 May)

The event brings together the CEOs and senior decision-makers from the world's most innovative biopharma, medtech and health tech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practices and forge partnerships and investments - all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes.

???? More information here.

• 20th CIMT Annual Meeting in Mainz (3-5 May)

The annual meeting connects the global cancer immunotherapy community in the heart of Europe. As the most significant meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education on cancer immunotherapy.

???? More information here.

• Spatial Biology: Translating basic?research into clinical insights in Singapore (5-6 May)

By enabling deeper analysis of the tumor microenvironment than permitted by single-plex techniques, multiplex imaging has broad-ranging benefits for researchers, clinicians, and drug developers.

???? More information here.

• 8th Annual School of Gastrointestinal Oncology in Orlando (6 May)

This is a 1-day multidisciplinary educational conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with gastrointestinal (GI) cancer.

???? More information here.

Every week you will find the best from LinkedIn. Stay tuned. ??

#biotechnology #linkedin #fundraising #events